Top

Published in:

01-04-2014 | Research Article

Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion

Authors: G. G. Sun, Y. F. Lu, J. Zhang, W. N. Hu

Published in: Tumor Biology | Issue 4/2014

Abstract

This study aims to analyze the expression and clinical significance of Filamin A (FLNA) in prostate carcinoma and the biological effect in its cell line by FLNA overexpression. Immunohistochemistry and Western blot were used to analyze FLNA protein expression in 68 cases of prostate cancer and 37 cases of normal tissues to study the influence of the upregulated expression of FLNA that might be found on PC-3 cell biological effect. In the immunohistochemical analysis, the level of FLNA protein expression was found to be significantly lower in prostate cancer tissue than in normal tissues (P < 0.05). In the Western blot analysis, the relative amount of FLNA protein in prostate cancer tissue was found to be significantly lower than in normal tissues (P < 0.05). The level of FLNA protein expression was not correlated with age and PSA concentration (P > 0.05), but it was correlated with T stages, lymph node metastasis, clinic stage, and Gleason score (P < 0.05). The result of biological function showed that PC-3 cell transfected FLNA had a lower survival fraction, a significant decrease in migration and invasion, and a lower matrix metallopeptidase 9 (MMP-9) protein expression compared with PC-3 cell untransfected FLNA (P < 0.05). FLNA expression decreased in prostate cancer and correlated significantly with T stages, lymph node metastasis, clinic stage, and Gleason score, suggesting that FLNA may play important roles as a negative regulator to prostate cancer PC-3 cell by promoting the degradation of MMP-9.

Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33.PubMedCrossRef

Dong JT, Isaacs WB, Isaacs JT. Molecular advances in prostate cancer. Curr Opin Oncol. 1997;9:101–7.PubMedCrossRef

Zhou X, Boren J, Akyurek LM. Filamins in cardiovascular development. Trends Cardiovasc Med. 2007;17:222–9.PubMedCrossRef

Ai J, Huang H, Lv X, Tang Z, Chen M, Chen T, et al. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell Physiol Biochem. 2011;27:207–16.PubMedCrossRef

Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol. 2001;2:138–45.PubMedCrossRef

Sheen VL, Feng Y, Graham D, Takafuta T, Shapiro SS, Walsh CA. Filamin A and Filamin B are co-expressed within neurons during periods of neuronal migration and can physically interact. Hum Mol Genet. 2002;11:2845–54.PubMedCrossRef

Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat Cell Biol. 2004;6:1034–8.PubMedCrossRef

Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, et al. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res. 2009;15:788–96.PubMedCentralPubMedCrossRef

Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem. 2007;282:19426–41.PubMedCrossRef

10.

Feng YY, Walsh CA. The many faces of flamin: a versatile molecular scaffold for cell motility and signaling. Nat Cell Biol. 2004;6:1034–8.PubMedCrossRef

11.

Nakamura F, Osborn TM, Hartemink CA, Hartwig JH, Stossel TP. Structure basis of filamin A functions. J Cell Biol. 2007;179:1011–25.PubMedCentralPubMedCrossRef

12.

Roberson SP, Twigg SR, Sutherland-Smith AJ, Biancalana V, Gorlin RJ, Horn D, et al. Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. Nat Genet. 2003;33:487–91.CrossRef

13.

Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res. 2006;5:1143–54.PubMedCrossRef

14.

Shi JW, Yu YM, Wang SJ, Zhang J, Wang GY. Expressions of filamin A and matrix metalloproteinase 9 in colorectal adenocarcinoma and their significance. Tumor. 2010;30:768–73.

15.

Wu YP, Li JB, Zhao RJ, Zhao RJ, Wang XL, Shan BE, et al. Expression of filamin A in invasive breast carcinoma and its significance. Tumor. 2009;29:659–62.

16.

Watanabe H. Extracellular matrix-regulation of cancer invasion and metastasis. Gan ToKagaku Ryoho. 2010;37:2058–61.

17.

Yu HB, Zhang HF, Li DY, Zhang X, Xue HZ, Zhao SH. Matrine inhibits matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. J Asian Nat Prod Res. 2011;13:242–50.PubMedCrossRef

18.

Zhang M, Zhu GY, Gao HY, Zhao SP, Xue Y. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in nasopharyngeal adenocarcinoma. J Surg Oncol. 2011;103:243–7.PubMedCrossRef

19.

Yang S, Du J, Wang Z, Yuan W, Qiao Y, Zhang M, et al. BMP-6 promotes E-cadherin expression through repressing delta EF1 in breast cancer cells. BMC Cancer. 2007;7:211.PubMedCentralPubMedCrossRef

20.

Onoprishvili I, Ali S, Andria ML, Shpigel A, Simon EJ. Filamin A mutant lacking actin-binding domain restores mu opioid receptor regulation in melanoma cells. Neurochem Res. 2008;33:2054–61.PubMedCrossRef

21.

Zhu TN, He HJ, Kole S, D'Souza T, Agarwal R, Morin PJ, et al. Filamin A-mediated down-regulation of the exchange factor Ras-GRF1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells. J Biol Chem. 2007;282:14816–26.PubMedCrossRef

22.

He HJ, Kole S, Kwon YK, Crow MT, Bernier M. Interaction of filamin A with the insulin receptor alters insulin-dependent activation of the mitogen-activated protein kinase pathway. J Biol Chem. 2003;278:27096–104.PubMedCrossRef

Title: Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion
Authors: G. G. Sun
Y. F. Lu
J. Zhang
W. N. Hu
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1504-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

The -786T > C polymorphism in the NOS3 gene is associated with increased cancer risk

NOV promoted the growth and migration of pancreatic cancer cells

Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell

Haplotype-based case–control study of DNA repair gene XRCC3 and hepatocellular carcinoma risk in a Chinese population

Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects

Polymorphisms of the XPC gene may contribute to the risk of head and neck cancer: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer